NEW YORK, NY / ACCESSWIRE / May 3, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Cronos Group Inc. (NASDAQ:CRON)
Class Period: May 9, 2019 to March 2, 2020
Lead Plaintiff Deadline: May 11, 2020
Cronos Group Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Cronos had engaged in significant transactions for which its revenue recognition was inappropriate; (ii) the foregoing would foreseeably necessitate reviews that would delay the Company's ability to timely file its periodic reports; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in CRON: http://www.kleinstocklaw.com/pslra-1/cronos-group-inc-loss-submission-form-2?id=6320&from=1
AnaptysBio, Inc. (NASDAQ:ANAB)
Class Period: October 10, 2017 to November 7, 2019
Lead Plaintiff Deadline: May 26, 2020
The ANAB lawsuit alleges AnaptysBio, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in ANAB: http://www.kleinstocklaw.com/pslra-1/anaptysbio-inc-loss-submission-form?id=6320&from=1
VMware, Inc. (NYSE:VMW)
Class Period: March 30, 2019 to February 27, 2020
Lead Plaintiff Deadline: June 1, 2020
The complaint alleges that during the class period VMware, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) VMware's reporting with respect to its backlog of unfilled orders was not in compliance with all relevant accounting and disclosure requirements; (ii) the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny and/or investigation; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in VMW: http://www.kleinstocklaw.com/pslra-1/vmware-inc-loss-submission-form?id=6320&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/588201/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-CRON-ANAB-and-VMW
